SERA Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -48837.5% compared to Sera Prognostics, Inc.'s net margin of 12.65%. Sera Prognostics, Inc.'s return on equity of -44.37% beat Electromed, Inc.'s return on equity of 18.89%.

Sera Prognostics, Inc. has a consensus price target of $5.00, signalling upside risk potential of 42.05%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 26.32%. Given that Sera Prognostics, Inc. has higher upside potential than Electromed, Inc., analysts believe Sera Prognostics, Inc. is more attractive than Electromed, Inc..

Sera Prognostics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Sera Prognostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sera Prognostics, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Sera Prognostics, Inc. quarterly revenues are $16K, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Sera Prognostics, Inc.'s net income of -$7.8M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Sera Prognostics, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sera Prognostics, Inc. is 1,616.41x versus 3.80x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of -48837.5% compared to Sera Prognostics, Inc.'s net margin of -36.3%. Sera Prognostics, Inc.'s return on equity of -44.37% beat Myomo, Inc.'s return on equity of -68.35%.

Sera Prognostics, Inc. has a consensus price target of $5.00, signalling upside risk potential of 42.05%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 390.2%. Given that Myomo, Inc. has higher upside potential than Sera Prognostics, Inc., analysts believe Myomo, Inc. is more attractive than Sera Prognostics, Inc..

Sera Prognostics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.

Sera Prognostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sera Prognostics, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

Sera Prognostics, Inc. quarterly revenues are $16K, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. Sera Prognostics, Inc.'s net income of -$7.8M is lower than Myomo, Inc.'s net income of -$3.7M. Notably, Sera Prognostics, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sera Prognostics, Inc. is 1,616.41x versus 1.00x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -48837.5% compared to Sera Prognostics, Inc.'s net margin of -862.39%. Sera Prognostics, Inc.'s return on equity of -44.37% beat VolitionRX Ltd.'s return on equity of --.

Sera Prognostics, Inc. has a consensus price target of $5.00, signalling upside risk potential of 42.05%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 780%. Given that VolitionRX Ltd. has higher upside potential than Sera Prognostics, Inc., analysts believe VolitionRX Ltd. is more attractive than Sera Prognostics, Inc..

Sera Prognostics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Sera Prognostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sera Prognostics, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Sera Prognostics, Inc. quarterly revenues are $16K, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Sera Prognostics, Inc.'s net income of -$7.8M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Sera Prognostics, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sera Prognostics, Inc. is 1,616.41x versus 17.13x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -48837.5% compared to Sera Prognostics, Inc.'s net margin of 3.93%. Sera Prognostics, Inc.'s return on equity of -44.37% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Sera Prognostics, Inc. has a consensus price target of $5.00, signalling upside risk potential of 42.05%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 93.3%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Sera Prognostics, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Sera Prognostics, Inc..

Sera Prognostics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Sera Prognostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sera Prognostics, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Sera Prognostics, Inc. quarterly revenues are $16K, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Sera Prognostics, Inc.'s net income of -$7.8M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Sera Prognostics, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sera Prognostics, Inc. is 1,616.41x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.